Aurubis AG
DUS:NDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurubis AG
DUS:NDA
|
DE |
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
AU |
|
E
|
EssilorLuxottica SA
MIL:EL
|
FR |
|
V
|
Valero Energy Corp
SWB:V1L
|
US |
|
Kko International SA
PAR:ALKKO
|
BE |
|
Amdocs Ltd
NASDAQ:DOX
|
US |
|
Siemens Healthineers AG
F:SHL
|
DE |
|
T
|
Tristate Holdings Ltd
XBER:TVX
|
HK |
|
I
|
International Container Terminal Services Inc
OTC:ICTEF
|
PH |
|
GlaxoSmithKline PLC
LSE:GSK
|
UK |
|
Jet2 PLC
LSE:JET2
|
UK |
|
S
|
Satin Creditcare Network Ltd
BSE:539404
|
IN |
|
G
|
Gamuda Bhd
KLSE:GAMUDA
|
MY |
|
D
|
Duopharma Biotech Bhd
KLSE:DPHARMA
|
MY |
|
Qudian Inc
NYSE:QD
|
CN |
Wall St Price Targets
NDA Price Targets Summary
Aurubis AG
According to Wall Street analysts, the average 1-year price target for NDA is 169.58 EUR with a low forecast of 111.1 EUR and a high forecast of 231 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NDA's stock price target?
Price Target
169.58
EUR
According to Wall Street analysts, the average 1-year price target for NDA is 169.58 EUR with a low forecast of 111.1 EUR and a high forecast of 231 EUR.
What is the Revenue forecast for Aurubis AG?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 7 years is 2%.
What is the Operating Income forecast for Aurubis AG?
Projected CAGR
-5%
Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 3 years is -5%.
What is the Net Income forecast for Aurubis AG?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Net Income has been 3%. The projected CAGR for the next 3 years is -2%.
